References
- Augenbraun M. Section 7: infectious disease. Chapter VI: syphilis and the nonvenereal treponematoses [update]. In: Dale DC, Federman DD, eds. ACP Medicine. Philadelphia, Pa: American College of Physicians; 2006:1-16.
- BICILLIN® L-A Prescribing Information. King Pharmaceuticals, 2006.
- BICILLIN® C-R Disposable Syringe Prescribing Information. King Pharmaceuticals, 2006.
- BICILLIN® C-R TUBEX Prescribing Information. Monarch Pharmaceuticals, 2004.
- BICILLIN® C-R 900/300 Prescribing Information. King Pharmaceuticals, 2006.
- CDC [Centers for Disease Control and Prevention]. Inadvertent use of BICILLIN® C-R to treat syphilis infection—Los Angeles, California, 1999-2004. MMWR Morbid Mortal Wkly Rep 2005;54:217-219.
- CDC [Centers for Disease Control and Prevention]. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR Morbid Mortal Wkly Rep 2006;55(RR-11):1-94.
- CDC [Centers for Disease Control and Prevention]. Syphilis Fact Sheet. May 2004.
- CDC [Centers for Disease Control and Prevention]. The National Plan to Eliminate Syphilis from the United States. May 2006.
- CDC [Centers for Disease Control and Prevention]. Trends in Reportable Sexually Transmitted Diseases in the United States, 2004. National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis. November 2005.
- 11. FDA [Food and Drug Administration]. FDA strengthens labels of two specific types of antibiotics to ensure proper use. FDA Talk Paper T04-54. December 1, 2004
- Hook EW III. Chapter 349: syphilis. Cecil Textbook of Medicine. 22nd ed. Elsevier; 2004.
- King Pharmaceuticals. “Dear Healthcare Professional” letter. 2004.
- Lukehart SA, Cogornes C, Moloni BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351:154-158.
- Peeling RW, Hook EW III. The pathogenesis of syphilis: the Great Mimicker, revisited. J Pathol 2006;208:224-232.
- WHO [World Health Organization]. STD Case Management Workbook 4: Diagnosis and Treatment. 1995.

